INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRIC RHEUMATOLOGY PRACTICE
https://doi.org/10.15690/vsp.v14i2.1290
Abstract
Modern successful treatment of rheumatic diseases is impossible without the use of intravenous immunoglobulin. The use of intravenous immunoglobulin is based on strict indications developed as a result of long-term multicenter controlled studies. The article highlights the issues of using immunoglobulin in pediatric rheumatology practice, and provides the review of literature with the results from the evaluation of the efficiency of intravenous immunoglobulin confirming the efficiency of the drug only for certain rheumatic diseases.
About the Authors
E. I. Alexeeva
Scientific Centre of Children’s Health, Moscow, Russian Federation
I.M. Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
A. M. Chomakhidze
Scientific Centre of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Cohn E.J. et al. The history of plasma fractionation. Advances in Military Medicine ed. E.C. Andrus. Boston. 1948; 1: 364–443.
2. Bruton O. Agammaglobulinemia. Pediatrics. 1952; 9: 722–728.
3. Aseeva E.A., Solov'ev S.K. Prospects for the use of intravenous immunoglobulin in autoimmune rheumatic diseases. Sovremennaya revmatologiya = Current rheumatology. 2014; 1: 45−52.
4. Schultze H.E., Schwik G. On new possibilities of intravenous gamma globulin administration. Dtsch Med Wochenschr.1962; 24 (87): 1643−1644.
5. Kondratenko I.V., Zaplatnikov A.L., Bologov A.A. Intravenous immunoglobulins. What and when. Detskaya bol'nitsa = Children's hospital. 2010; 4: 50−60.
6. Kazatchkine M., Kaveri S. Immunomodulation of autoimmune and inflammatory diseases witch intravenous immune giobulin. N. Engl. J. Med. 2001; 34: 747−755.
7. Averchenkov V.M., Palagin I.S. Intravenous immunoglobulin: mechanism of action and clinical applications. Klinicheskaya mikrobiologicheskaya i antimikrobnaya khimioterapiya = Clinical microbiology and antimicrobial chemotherapy. 2004; 6 (3): 273−281.
8. Negi V.-S., Elluru S., Siberil S. et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immun. 2007; 27 (3): 233−245.
9. Fridmann W. Regulation of B-cell activation and antigen presentation by Fc-receptors. Curr. Opin. Immunol. 1993; 340 (3): 355−360.
10. Yu Z., Lennon V. Mechanism of intravenous immunoglobuline therapy in antibody-mediated autoimmune diseases. N. Engl. J. Med. 1999; 340 (3): 227−228.
11. Bleeker W., Teeling J., Hack C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy experimental models of determine the magnitude and time course of the effect. Blood. 2001; 98 (10): 3136−3142.
12. Mollnes T., Hogasen K., Hoass B. et al. Inhibition of complement-mediated red cells lysis by immunoglobulins is depended on the ig isitype and its C1 binding proteins. Scand. J. Immunol. 1995; 41 (5): 449−456.
13. Prasad N., Papoff G., Zeuner A. et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induse apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IV Ig involving the Fas apoptosic pathway. J. Immunol. 1998; 161: 3781−3790.
14. Averchenkov V.M., Palagin I.S. Intravenous immunoglobulin: mechanism of action and clinical applications. Klinicheskaya mikrobiologicheskaya i antimikrobnaya khimioterapiya = Clinical microbiology and antimicrobial chemotherapy. 2004; 6 (3): 273−281.
15. Alekseeva E.I., Isaeva K.B., Shakhbazyan I.E., Zholobova E.S. The effectiveness of intravenous immunoglobulin treatment of patients with systemic type of juvenile rheumatoid arthritis. Klinicheskaya meditsina = Clinical medicine. 2001; 2: 30−33.
16. AI-Mayouf S.M. et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 2000; 27: 2498−2503.
17. Ballow M., Park A. The uses of intravenous immune globulin in collagen vascular disoders. J. Allergy Clin. Immunol. 1989; 84 (4 Pt. 2): 608−612.
18. Jayne D.R., Chapel H., Adu D. et al. Intravenous immunoglobuline for ANCA-associated systemic vasculitis with persistant disease activity. QJM. 2009; 93 (7): 433−439.
19. Atlas po detskoi revmatologii. Pod red. A.A. Baranova, E.I. Alekseevoi [Atlas of Pediatric Rheumatology. Edited by A.A. Baranov, E.I. Alexeeva]. Moscow, Pediatr"", 2009. 248 p.
20. Silverman E.D., Cawkwell G.D., Lovell D.G. et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomisrd placebo controlled trial. J. Rheumatol. 1994; 21 (120): 2353−2358.
21. Gianini E.N., Lovell D.S. et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis. A phase I/II stady. J. Rheumatol. 1996; 23: 919−924.
22. Permal S., Wechsler B., Cabane J. et al. Treatment of Stills deseas in adults with intravenous immunoglobuline. Rev. Med. Interne.1995; 16 (4): 250−254.
23. Prieur S., Wechsler B., Debre V. et al. High dose immunoglobulin therapy in serve juvenile chronic arthritis: longterm follow up in 16 patients. Clin. Exp. Rheumatol. 1990; 8 (6): 603−608.
24. Vaitla P.M., McDermott E.M. The role of high-dose intravenous immunoglobuline in rheumatology. Rheumatology (Oxford). 2010; 49 (6): 1040−1048.
25. Opperman J., Mobius D. Therapeutical and immunological effects of methylprednisolone pulss therapy in comparison with intravenous immunoglobuline treatment in patients with juvenile chronic arthritis. Acta Universitis Caroline Medica. 1994; 40 (1−4): 117−121.
26. Valieva S.I., Alekseeva E.I., Akulova S.S. et al. Efficacy and safety of prolonged use of rituximab in patients with systemic juvenile idiopathic arthritis. Voprosy sovremennoi pediatrii = Current pediatrics. 2013; 12 (2): 89–100.
27. Maschan M.A., Poltavets N.V. Hemophagocytic syndrome in pediatric emergency. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (2): 15−21.
28. Rosário С. et al. The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Medicine. 2013, 11: 185.
29. Lang B.A. et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am. J. Med. 1991; 8: 169−182.
30. Wedderburn L.R., Rider L.G. Best Pract. Res. Clin. Rheumatol. 2009; 23: 655−678.
31. Al-Mayouf S.M., Laxer R.M., Schneider R. et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 2000; 27 (10): 2498–2503.
32. Deborah M. Levy et al. Favorable Outcome of Juvenile Dermatomyositis Treated Without Systemic Corticosteroids. J. Pediatr. 2010; 156 (2): 302–307.
33. Vaitla P.M., McDermott E.M. The role of high-dose intravenous immunoglobuline in rheumatology. Rheumatology (Oxford). 2010; 49 (6): 1040−1048.
34. Gokce M., Bilginer Y., Besbas N. et al. Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children. Lupus. 2012; 21: 878–888.
35. Chetan G., Mahadevan S., Sulanthung K., Narayana P. Intravenous Immunoglobulin Therapy of Lupus Pneumonitis. Indian J. Pediatrics. 2007; 74 (11): 1032−1033.
36. Suri V., Varma S., Joshi K. et al. Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy. Rheumatol. Int. 2010; 30: 1503–1505.
37. Boletis J.N., Ioannidis J.R., Boki K.A. et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999; 354 (9178): 569−570.
38. Bucciarelli S., Espinosa G., Cervera R. et al. Mortality in the Catastrophic Antiphospholipid Syndrome. Causes of Death and Prognostic Factors in Series of 250 Patients. Arthritis Rheum. 2006; 54 (8): 2568−2576.
39. Caccavo D., Vaccaro F., Ferry G.M. et al. Antiidiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J. Autoimmun. 1994; 21 (12): 2353−2358.
40. Tenti S., Guidelli G.M., Bellisai F., Galeazzi M. et al. Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy. Clin. Exp. Rheumatol. 2013; 1−6.
41. Furusho K., Sato K., Soeda T. et al. High-dose intravenous gammaglobulinfor Kawasaki diseas. Lancet. 1983; 2 (8363): 1359.
42. Oates-Whitehead R.M., Baumer J.N. et al. Intravenous immunoglobuline for the treatment of Kawasaki diseas in children. Cochrane Database Syst. Rev. 2003; 4: CD004000.
43. Eleftheriou D. et al. Management of Kawasaki disease. Arch. Dis. Child. 2014; 99: 74–83.
44. Boman S., Ballen J.L., Seggev J.S. et al. Dramatic responses to intravenous immunoglobulin in vasculitis. J. Int. Med. 1995; 238 (4): 375−377.
45. Jayne D.R., Lockwood C.M., Fox J.L. et al. Intravenous immunoglobulin as sole for the systemic vasculitis. Brit. J. Rheumatol. 1996; 35 (11): 1150−1153.
46. Jayne D.R., Chapel H., Adu D. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistant disease activity. QJM. 2009; 93 (7): 433−439.
47. Pamela F. Weiss. Pediatric Vasculitis. Pediatr. Clin. North Am. 2012; 59 (2): 407–423.
48. Toussaint S., Geriach H. Immunoglobulins in Adult Sepsis and Septic Shock. Curr. Infect. Dis. Rep. 2012; 14 (5): 522–529.
49. Duhem C., Dicato M., Ries F. Side effects of intravenous immunоglobulins. Clin. Exp. Immunol. 1994; 97 (Suppl. I): 79−83.
50. Ryan M., Webster M., Statler J. Adverse effects of intravenous immunoglobulin therapy. Clin. Pediatr. 1996; 35: 23−31.
51. Strangel M., Hartung H., Marx P., Gold R. Side effects of high dose intravenous immunoglobulins. Clin. Neuropharmacol. 1997; 20: 385−393.
52. Burks A., Sampson H., Buckley R. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N. Engl. J. Med. 1986; 314: 560−563.
53. Orbach H. et al. Intravenous Immunoglobulin Adverse Effects and Safe Administratio. Clin. Rev. Allergy Immunol. 2005; 29: 173−184.
Review
For citations:
Alexeeva E.I., Denisova R.V., Chomakhidze A.M. INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRIC RHEUMATOLOGY PRACTICE. Current Pediatrics. 2015;14(2):219-223. (In Russ.) https://doi.org/10.15690/vsp.v14i2.1290
Views:
1010
Email this article 
